EFICACIA DEL CANNABIDIOL EN EPILEPSIA REFRACTARIA: REVISIÓN DE ALCANCE SOBRE REDUCCIÓN DE CRISIS FRENTE A PLACEBO Y TRATAMIENTO FARMACOLÓGICO COMBINADO.
Saved in:
| Title: | EFICACIA DEL CANNABIDIOL EN EPILEPSIA REFRACTARIA: REVISIÓN DE ALCANCE SOBRE REDUCCIÓN DE CRISIS FRENTE A PLACEBO Y TRATAMIENTO FARMACOLÓGICO COMBINADO. |
|---|---|
| Alternate Title: | EFFICACY OF CANNABIDIOL IN DRUG%RESISTANT EPILEPSY: A SCOPING REVIEW ON SEIZURE REDUCTION COMPARED TO PLACEBO AND COMBINED PHARMACOTHERAPY. |
| Authors: | ARCINIEGAS CHAMORRO, JACSON FRANCISMO1, SANCLEMENTE-CARDOZA, VALERIA1, DAYANA NOREÑA-BUITRÓN, LIZETH1, ESTELA ZAPE, JOSE LUIS2 |
| Source: | Revista Médica de Rosario. sep-dic2025, Vol. 91 Issue 3, p164-178. 15p. |
| Subjects: | CANNABIDIOL, TREATMENT effectiveness, LENNOX-Gastaut syndrome, DRUG therapy, INFANTILE spasms, DRUG side effects, ANTICONVULSANTS |
| Abstract (English): | Introduction: Refractory epilepsy poses a clinical challenge due to resistance to multiple antiepileptic drugs, adversely a#ecting seizure control and quality of life. In this context, cannabidiol (CBD) has emerged as an adjunct therapeutic option. Objective: To evaluate the efficacy of CBD in reducing seizures in refractory epilepsy patients, comparing its e#ect against placebo and combined pharmacological treatments. Methods: A systematic review was conducted in PubMed, ScienceDirect, Scopus, and Web of Science using specific keywords such as "Cannabinoids" and "Drug-Resistant Epilepsy." Study selection involved independent screening and application of inclusion criteria prior to critical appraisal, data extraction, and risk of bias assessment. Results: From 2,909 identified articles, 26 studies were included with follow-up ranging from 10 weeks to 3 years. CBD dosages varied across populations; generalized tonic-clonic seizures were the most prevalent (66%). All patients received concomitant antiepileptic therapy. Adjunctive CBD reduced seizure frequency by 28% at 14 weeks and up to 75% at 7 months. In Lennox-Gastaut syndrome, the mean monthly seizure reduction was 36.5%. In Dravet syndrome, CBD modulated intracellular calcium via GPR55 receptors and VDAC1 channels, decreasing neuronal excitability. Reported adverse effects included somnolence, anorexia, and diarrhea in 5% of patients. Conclusions: CBD demonstrated efficacy in refractory epilepsy, particularly at doses of 25-50 mg/kg/day, with a favorable safety profile, representing a therapeutic alternative in cases resistant to conventional treatments. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | Introducción: La epilepsia refractaria constituye un reto clínico debido a la resistencia a múltiples fármacos antiepilépticos, impactando negativamente el control convulsivo y la calidad de vida. En este contexto, el cannabidiol (CBD) surge como opción terapéutica adyuvante. Objetivo: Evaluar la eficacia del CBD en la reducción de convulsiones en epilepsia refractaria, comparando su efecto frente a placebo y tratamientos farmacológicos combinados. Métodos: Se realizó una revisión en PubMed, ScienceDirect, Scopus y Web of Science, empleando términos específicos como "Cannabinoids" y "Drug-Resistant Epilepsy". La selección incluyó filtrado independiente y aplicación de criterios de inclusión antes de lectura crítica, extracción de datos y evaluación del riesgo de sesgo. Resultados: De 2,909 artículos identificados, se incluyeron 26 estudios con seguimiento de 10 semanas a 3 años. Las dosis de CBD variaron según la población; la crisis tónico-clónica generalizada fue la más frecuente (66%). Todos los pacientes recibían terapia antiepiléptica concomitante. La adición de CBD redujo la frecuencia convulsiva entre 28% a 14 semanas y hasta 75% a 7 meses. En síndrome de Lennox-Gastaut, la reducción media mensual fue 36.5%. En síndrome de Dravet, el CBD moduló el calcio intracelular vía receptores GPR55 y canales VDAC1, disminuyendo la excitabilidad neuronal. Los efectos adversos reportados incluyeron somnolencia, anorexia y diarrea en 5% de pacientes. Conclusiones: El CBD demostró eficacia en epilepsia refractaria, especialmente en dosis de 25-50 mg/kg/día, con perfil de seguridad favorable, constituyendo una alternativa terapéutica en casos resistentes a tratamientos convencionales. [ABSTRACT FROM AUTHOR] |
| Copyright of Revista Médica de Rosario is the property of Circulo Medico de Rosario and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 191648972 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: EFICACIA DEL CANNABIDIOL EN EPILEPSIA REFRACTARIA: REVISIÓN DE ALCANCE SOBRE REDUCCIÓN DE CRISIS FRENTE A PLACEBO Y TRATAMIENTO FARMACOLÓGICO COMBINADO. – Name: TitleAlt Label: Alternate Title Group: TiAlt Data: EFFICACY OF CANNABIDIOL IN DRUG%RESISTANT EPILEPSY: A SCOPING REVIEW ON SEIZURE REDUCTION COMPARED TO PLACEBO AND COMBINED PHARMACOTHERAPY. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22ARCINIEGAS+CHAMORRO%2C+JACSON+FRANCISMO%22">ARCINIEGAS CHAMORRO, JACSON FRANCISMO</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22SANCLEMENTE-CARDOZA%2C+VALERIA%22">SANCLEMENTE-CARDOZA, VALERIA</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22DAYANA+NOREÑA-BUITRÓN%2C+LIZETH%22">DAYANA NOREÑA-BUITRÓN, LIZETH</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22ESTELA+ZAPE%2C+JOSE+LUIS%22">ESTELA ZAPE, JOSE LUIS</searchLink><relatesTo>2</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Revista+Médica+de+Rosario%22">Revista Médica de Rosario</searchLink>. sep-dic2025, Vol. 91 Issue 3, p164-178. 15p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22CANNABIDIOL%22">CANNABIDIOL</searchLink><br /><searchLink fieldCode="DE" term="%22TREATMENT+effectiveness%22">TREATMENT effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22LENNOX-Gastaut+syndrome%22">LENNOX-Gastaut syndrome</searchLink><br /><searchLink fieldCode="DE" term="%22DRUG+therapy%22">DRUG therapy</searchLink><br /><searchLink fieldCode="DE" term="%22INFANTILE+spasms%22">INFANTILE spasms</searchLink><br /><searchLink fieldCode="DE" term="%22DRUG+side+effects%22">DRUG side effects</searchLink><br /><searchLink fieldCode="DE" term="%22ANTICONVULSANTS%22">ANTICONVULSANTS</searchLink> – Name: Abstract Label: Abstract (English) Group: Ab Data: Introduction: Refractory epilepsy poses a clinical challenge due to resistance to multiple antiepileptic drugs, adversely a#ecting seizure control and quality of life. In this context, cannabidiol (CBD) has emerged as an adjunct therapeutic option. Objective: To evaluate the efficacy of CBD in reducing seizures in refractory epilepsy patients, comparing its e#ect against placebo and combined pharmacological treatments. Methods: A systematic review was conducted in PubMed, ScienceDirect, Scopus, and Web of Science using specific keywords such as "Cannabinoids" and "Drug-Resistant Epilepsy." Study selection involved independent screening and application of inclusion criteria prior to critical appraisal, data extraction, and risk of bias assessment. Results: From 2,909 identified articles, 26 studies were included with follow-up ranging from 10 weeks to 3 years. CBD dosages varied across populations; generalized tonic-clonic seizures were the most prevalent (66%). All patients received concomitant antiepileptic therapy. Adjunctive CBD reduced seizure frequency by 28% at 14 weeks and up to 75% at 7 months. In Lennox-Gastaut syndrome, the mean monthly seizure reduction was 36.5%. In Dravet syndrome, CBD modulated intracellular calcium via GPR55 receptors and VDAC1 channels, decreasing neuronal excitability. Reported adverse effects included somnolence, anorexia, and diarrhea in 5% of patients. Conclusions: CBD demonstrated efficacy in refractory epilepsy, particularly at doses of 25-50 mg/kg/day, with a favorable safety profile, representing a therapeutic alternative in cases resistant to conventional treatments. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Spanish) Group: Ab Data: Introducción: La epilepsia refractaria constituye un reto clínico debido a la resistencia a múltiples fármacos antiepilépticos, impactando negativamente el control convulsivo y la calidad de vida. En este contexto, el cannabidiol (CBD) surge como opción terapéutica adyuvante. Objetivo: Evaluar la eficacia del CBD en la reducción de convulsiones en epilepsia refractaria, comparando su efecto frente a placebo y tratamientos farmacológicos combinados. Métodos: Se realizó una revisión en PubMed, ScienceDirect, Scopus y Web of Science, empleando términos específicos como "Cannabinoids" y "Drug-Resistant Epilepsy". La selección incluyó filtrado independiente y aplicación de criterios de inclusión antes de lectura crítica, extracción de datos y evaluación del riesgo de sesgo. Resultados: De 2,909 artículos identificados, se incluyeron 26 estudios con seguimiento de 10 semanas a 3 años. Las dosis de CBD variaron según la población; la crisis tónico-clónica generalizada fue la más frecuente (66%). Todos los pacientes recibían terapia antiepiléptica concomitante. La adición de CBD redujo la frecuencia convulsiva entre 28% a 14 semanas y hasta 75% a 7 meses. En síndrome de Lennox-Gastaut, la reducción media mensual fue 36.5%. En síndrome de Dravet, el CBD moduló el calcio intracelular vía receptores GPR55 y canales VDAC1, disminuyendo la excitabilidad neuronal. Los efectos adversos reportados incluyeron somnolencia, anorexia y diarrea en 5% de pacientes. Conclusiones: El CBD demostró eficacia en epilepsia refractaria, especialmente en dosis de 25-50 mg/kg/día, con perfil de seguridad favorable, constituyendo una alternativa terapéutica en casos resistentes a tratamientos convencionales. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Revista Médica de Rosario is the property of Circulo Medico de Rosario and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=191648972 |
| RecordInfo | BibRecord: BibEntity: Languages: – Code: spa Text: Spanish PhysicalDescription: Pagination: PageCount: 15 StartPage: 164 Subjects: – SubjectFull: CANNABIDIOL Type: general – SubjectFull: TREATMENT effectiveness Type: general – SubjectFull: LENNOX-Gastaut syndrome Type: general – SubjectFull: DRUG therapy Type: general – SubjectFull: INFANTILE spasms Type: general – SubjectFull: DRUG side effects Type: general – SubjectFull: ANTICONVULSANTS Type: general Titles: – TitleFull: EFICACIA DEL CANNABIDIOL EN EPILEPSIA REFRACTARIA: REVISIÓN DE ALCANCE SOBRE REDUCCIÓN DE CRISIS FRENTE A PLACEBO Y TRATAMIENTO FARMACOLÓGICO COMBINADO. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: ARCINIEGAS CHAMORRO, JACSON FRANCISMO – PersonEntity: Name: NameFull: SANCLEMENTE-CARDOZA, VALERIA – PersonEntity: Name: NameFull: DAYANA NOREÑA-BUITRÓN, LIZETH – PersonEntity: Name: NameFull: ESTELA ZAPE, JOSE LUIS IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 09 Text: sep-dic2025 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 03275019 Numbering: – Type: volume Value: 91 – Type: issue Value: 3 Titles: – TitleFull: Revista Médica de Rosario Type: main |
| ResultId | 1 |
